Caladrius Biosciences Inc. | Mutual Funds
Mutual Funds that own Caladrius Biosciences Inc.
Vanguard Total Stock Market Index Fund
174,630
1.8%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
37,008
0.38%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
23,398
0.24%
5,700
0%
07/31/2018
iShares Micro Cap ETF
22,623
0.23%
0
0.01%
09/06/2018
DFA US Core Equity 2 Portfolio
20,846
0.21%
12,529
0%
04/30/2018
Fidelity Spartan Total Market Index Fund
9,530
0.1%
0
0%
07/31/2018
DFA US Core Equity 1 Portfolio
5,800
0.06%
5,800
0%
04/30/2018
DFA Tax Managed US Targeted Value Portfolio
5,102
0.05%
5,102
0%
04/30/2018
iShares Core S&P Total US Stock Market ETF
3,814
0.04%
0
0%
09/06/2018
Vanguard Total Stock Market Index Trust
2,120
0.02%
0
0%
07/31/2018
| Address |
110 Allen Road
Basking Ridge New Jersey 07920
United States
|
|
Employees
|
- |
| Website |
http://www.caladrius.com |
| Updated |
07/08/2019 |
| Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. Its business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products. |
